News + Events2018-11-08T22:46:29+00:00

Latest Press Releases

Cadent Therapeutics Secures $40 Million Series B Financing to Advance Pipeline of Novel Therapies for Movement and Cognitive Disorders

November 15th, 2018|

Cadent Therapeutics, a company focused on the development of breakthrough therapies to improve the lives of patients with movement and cognitive disorders, today announced that it has raised $40 million in a Series B financing. In addition, the company has appointed Bob (Ibrahim) Dagher, M.D., as Chief Medical Officer.

Cadent Therapeutics Initiates Phase 1 Study of Lead Compound CAD-1883

March 12th, 2018|

Cadent Therapeutics, a precision neuroscience company developing novel medicines to restore movement and cognitive function in patients with neurological and psychiatric disease, today announced the initiation of a Phase 1 clinical study for its lead product candidate CAD-1883. The compound is a selective first-in-class positive allosteric modulator of the small conductance calcium-activated potassium (SK) channel.